QIAGEN Exceeds Outlook in First Quarter 2021 Results, Reaffirms Sales Growth and Profitability Outlook for Full-Year 2021
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Qiagen (QGEN) Tops Q1 EPS by 3c, Revenues Beat; Reaffirms FY21 EPS Outlook
May 3, 2021 4:26 PM EDTQiagen (NYSE: QGEN) reported Q1 EPS of $0.66, $0.03 better than the analyst estimate of $0.63. Revenue for the quarter came in at $567.2 million versus the consensus estimate of $557.5 million.
Q1 2021 net sales rise 52% (48% CER) to $567.2 million, exceeds outlook for at least 45% CER growth; adj. EPS up 94% to $0.66 ($0.65 CER), exceeds outlook for ~$0.60-0.62 CER16% CER growth to $364 million from non-COVID product groups, represent 64% of total sales, while COVID-19 product group sales rise 186% CER to $203 millionQ1 2021 operating cash flow rises over 700% to $128.6 million, free... More